Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting IL-23 in autoimmunity.

Christoph Hölscher1

  • 1Junior Research Group Molecular Infection Biology, Research Center Borstel, Parkallee 22, D-23845 Borstel, Germany. choelscher@fz-borstel.de

Current Opinion in Investigational Drugs (London, England : 2000)
|May 26, 2005
PubMed
Summary

Interleukin-23 (IL-23) drives autoimmune inflammation, not IL-12. Targeting IL-23 offers a promising therapeutic strategy for autoimmune diseases by modulating cell-mediated immunity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond traditional assessments of cognitive status: Exploring the potential of spatial navigation tasks.

Behavior research methods·2026
Same author

Kupffer cell plasticity regulates hepatic immunity in mycobacterial infection.

Journal of hepatology·2026
Same author

C1q and mannose-binding lectin binding and complement activation across genetically diverse Mycobacterium tuberculosis complex strains.

Journal of immunology (Baltimore, Md. : 1950)·2025
Same author

Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models.

The Journal of infectious diseases·2025
Same author

The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis.

Nature communications·2025
Same author

The molecular bacterial load assay predicts treatment responses in patients with pre-XDR/XDR-tuberculosis more accurately than GeneXpert Ultra MTB/Rif.

The Journal of infection·2024

Area of Science:

  • Immunology
  • Autoimmune Diseases
  • Cellular Immunity

Background:

  • Dysregulated cell-mediated immune responses are implicated in chronic inflammation and autoimmune disorders.
  • Interleukin-23 (IL-23), a cytokine related to IL-12, plays a crucial role in fine-tuning cellular immunity.
  • Previous understanding of IL-12p40's role in autoimmune inflammation was limited; recent studies highlight IL-23 as the key factor.

Purpose of the Study:

  • To summarize recent findings on IL-23-mediated autoreactive inflammatory responses.
  • To introduce potential therapeutic interventions targeting IL-23 for autoimmune diseases.

Main Methods:

  • Literature review of recent studies on IL-23 and autoimmune inflammation.
  • Analysis of the role of IL-23 and its receptor in immune deviation.
  • Identification of therapeutic targets for autoimmune disease mitigation.

Main Results:

  • IL-23, not IL-12, is identified as the decisive factor in autoimmune inflammation.
  • Targeting IL-23 or its receptor presents a promising therapeutic avenue.
  • IL-23 mediates autoreactive inflammatory responses contributing to autoimmune conditions.

Conclusions:

  • IL-23 is a critical mediator of autoimmune inflammation.
  • Therapeutic strategies targeting IL-23 hold significant potential for treating autoimmune diseases.
  • Modulating IL-23 signaling can help mitigate autoimmune inflammatory responses.

Related Experiment Videos